Who Is Heidi Overton? Meet Trump’s FDA Commissioner Pick as Agency Faces Major Shake-Up

President Donald Trump on Wednesday, August 19, 2026, nominated Dr. Heidi Overton to lead the Food and Drug Administration, putting a White House health-policy insider at the center of an agency undergoing one of its most consequential periods of change.

Overton will need Senate confirmation before she can take over the FDA permanently. The nomination makes Overton a particularly important figure in Trump’s second-term health agenda.

A physician with experience in surgery, clinical investigation and health policy, she has worked closely with Health and Human Services Secretary Robert F. Kennedy Jr. and Medicare and Medicaid chief Dr. Mehmet Oz.

Trump said she would help pursue faster cures, clinical-trial reforms, greater U.S. innovation and lower drug prices.

Who Is Heidi Overton?

Overton is currently a deputy assistant to the president for domestic policy at the White House.

Before joining the administration, she served as chief policy officer and vice chair of the Center for a Healthy America at the conservative America First Policy Institute.

Her medical background is extensive.

She earned her undergraduate and medical degrees through the University of New Mexico’s combined BA/MD program, completed general surgery residency training at Johns Hopkins University and earned a Ph.D. in clinical investigation from the Johns Hopkins Bloomberg School of Public Health.

She also served as a White House fellow during Trump’s first term.

That combination of medical training and policy experience has made her an influential behind-the-scenes figure in Trump’s health agenda.

Why Trump Chose Overton

Trump’s announcement places Overton firmly within the administration’s effort to reshape federal health policy.

In announcing her nomination, Trump said Overton would work with Kennedy and Oz to deliver “FASTER Cures, INCREASED American Innovation, MAJOR Clinical Trial Reforms, LOWER Drug Prices” and other Make America Healthy Again priorities.

Overton has already played a role in several administration health initiatives, including work involving the childhood vaccine schedule, food policy and pharmaceutical pricing.

STAT reported that she had become a powerful health-policy voice inside the administration.

Her involvement in the administration’s vaccine policy has also drawn attention.

She was among the officials present when Trump signed an August 10 executive order recommending changes to childhood vaccine policy, including a move toward separating the measles, mumps and rubella vaccine into individual shots.

Overton’s Views Could Draw Senate Scrutiny

Her policy record is likely to receive close examination during confirmation hearings.

Overton has previously written and spoken about abortion policy and medication abortion, including criticism of the expansion of telehealth-based abortion-pill access.

Her work at the America First Policy Institute placed her on the conservative side of debates over reproductive policy.

Her views on vaccines and her close alignment with Trump’s health agenda could likewise become major issues in the Senate.

The confirmation process will allow lawmakers to question how she would balance the administration’s policy priorities with the FDA’s traditional responsibilities for evaluating drugs, vaccines, medical devices and food safety.

Why the FDA Leadership Change Matters

The timing of Overton’s nomination is significant because the FDA has been operating without a permanent commissioner since Dr. Marty Makary’s departure in May.

Acting Commissioner Kyle Diamantas has been running the agency in the interim.

Makary’s exit followed tensions within the administration, including disagreements surrounding flavored e-cigarettes and other regulatory decisions.

The agency has also experienced substantial personnel losses.

Reuters reported that more than 3,000 FDA employees, including senior division leaders, have left over the past year, raising concerns about institutional stability and confidence in the regulator.

That leaves Overton facing a much larger challenge than simply filling a vacant leadership position.

If confirmed, she would inherit an agency dealing with workforce disruption, contentious vaccine and reproductive-health policies, pharmaceutical regulation and pressure to accelerate drug development.

The Next Steps

Overton’s nomination now moves to the Senate, where lawmakers will examine her qualifications, policy positions and plans for the FDA before voting on confirmation.

Until then, Diamantas remains the acting commissioner.

The key question for the FDA will be whether Overton can translate Trump’s health-policy priorities into regulatory decisions while maintaining the agency’s scientific and public-health responsibilities.

For consumers, drugmakers and the broader health-care industry, her confirmation could help determine the direction of FDA policy on vaccines, medicines, clinical trials, food regulation and drug pricing for the remainder of Trump’s term.